NI201700035A - Uso de paneles de genes mutantes del fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor del fgfr - Google Patents

Uso de paneles de genes mutantes del fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor del fgfr

Info

Publication number
NI201700035A
NI201700035A NI201700035A NI201700035A NI201700035A NI 201700035 A NI201700035 A NI 201700035A NI 201700035 A NI201700035 A NI 201700035A NI 201700035 A NI201700035 A NI 201700035A NI 201700035 A NI201700035 A NI 201700035A
Authority
NI
Nicaragua
Prior art keywords
fgfr
respond
treatment
cancer patients
identification
Prior art date
Application number
NI201700035A
Other languages
English (en)
Inventor
Karkera Jayaprakash
Jesus Platero Suso
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54337343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201700035(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NI201700035A publication Critical patent/NI201700035A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se describen en la presente métodos para identificar un paciente con cáncer que responderá al tratamiento con un inhibidor del receptor del factor de crecimiento de fibroblastos (FGFR) y métodos para tratar pacientes con cáncer. Los métodos implican evaluar una muestra biológica del paciente para la presencia de uno o más mutantes del FGFR de un panel de genes mutantes del FGFR. También se describen en el presente documento, kits y cebadores para identificar la presencia de uno o más genes mutantes del FGFR en una muestra biológica.
NI201700035A 2014-09-26 2017-03-24 Uso de paneles de genes mutantes del fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor del fgfr NI201700035A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462056159P 2014-09-26 2014-09-26

Publications (1)

Publication Number Publication Date
NI201700035A true NI201700035A (es) 2017-06-22

Family

ID=54337343

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201700035A NI201700035A (es) 2014-09-26 2017-03-24 Uso de paneles de genes mutantes del fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor del fgfr

Country Status (38)

Country Link
US (3) US20160090633A1 (es)
EP (2) EP4063516A1 (es)
JP (4) JP6766037B2 (es)
KR (3) KR102470456B1 (es)
CN (2) CN107002141B (es)
AR (1) AR102345A1 (es)
AU (3) AU2015321626B2 (es)
CA (1) CA2962075C (es)
CO (1) CO2017003528A2 (es)
CR (1) CR20170104A (es)
CY (1) CY1125190T1 (es)
DK (1) DK3198033T3 (es)
EA (1) EA037920B1 (es)
EC (1) ECSP17025787A (es)
ES (1) ES2912567T3 (es)
GT (1) GT201700059A (es)
HR (1) HRP20220496T1 (es)
HU (1) HUE058219T2 (es)
IL (3) IL291633B2 (es)
JO (1) JO3681B1 (es)
LT (1) LT3198033T (es)
MA (1) MA40761B1 (es)
MX (2) MX392774B (es)
MY (1) MY194567A (es)
NI (1) NI201700035A (es)
PH (1) PH12017500556A1 (es)
PL (1) PL3198033T3 (es)
PT (1) PT3198033T (es)
RS (1) RS63178B1 (es)
SG (1) SG11201702381QA (es)
SI (1) SI3198033T1 (es)
SM (1) SMT202200177T1 (es)
SV (1) SV2017005415A (es)
TW (1) TWI706136B (es)
UA (1) UA122564C2 (es)
UY (1) UY36325A (es)
WO (1) WO2016048833A2 (es)
ZA (1) ZA201702899B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2886002C (en) 2012-09-27 2020-06-09 Chugai Seiyaku Kabushiki Kaisha Fgfr3 fusion gene and pharmaceutical drug targeting same
JP6731254B2 (ja) 2014-01-24 2020-07-29 公益財団法人がん研究会 新規融合体及びその検出法
JP6752715B2 (ja) 2014-03-26 2020-09-09 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 組合せ
EP4063516A1 (en) 2014-09-26 2022-09-28 Janssen Pharmaceutica NV Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) * 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP3424505A4 (en) * 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
JOP20190280A1 (ar) 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
AU2019310601A1 (en) 2018-07-27 2021-02-04 Zepto Life Technology, Inc. System and method for sensing analytes in GMR-based detection of biomarkers
EP3852756A1 (en) * 2018-09-21 2021-07-28 Janssen Pharmaceutica NV Treatment of cholangiocarcinoma
PH12021551949A1 (en) * 2019-02-12 2022-07-18 Janssen Pharmaceutica Nv Cancer treatment
AU2020253827B2 (en) 2019-03-29 2026-01-08 Janssen Pharmaceutica Nv FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma
SG11202109854RA (en) 2019-03-29 2021-10-28 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
US20220233537A1 (en) * 2019-05-31 2022-07-28 Qed Therapeutics, Inc. Methods of treating urinary system cancers
CN110241183B (zh) * 2019-06-13 2022-10-28 南京世和基因生物技术股份有限公司 一种fgfr融合基因的检测方法、试剂盒以及探针库
JPWO2021010326A1 (es) * 2019-07-12 2021-01-21
CN115335701A (zh) * 2019-09-09 2022-11-11 泽普托生命技术有限责任公司 用于检测核酸中基因变异的系统和方法
AU2020352668A1 (en) 2019-09-26 2022-03-31 Janssen Pharmaceutica Nv Use of FGFR inhibitors in FGFR-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
EP4087625A4 (en) 2020-01-08 2024-03-13 Zepto Life Technology, LLC POLYMER COMPOSITIONS AND BIOSURFACES INCLUDING THEM ON SENSORS
MX2022009905A (es) 2020-02-12 2022-08-25 Janssen Pharmaceutica Nv Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto.
TWI900527B (zh) 2020-02-12 2025-10-11 比利時商健生藥品公司 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
MX2022012982A (es) * 2020-04-15 2023-03-06 Alkermes Pharma Ireland Ltd Agentes inmunoestimulantes en combinación con inhibidores de la angiogénesis.
CN111440790A (zh) * 2020-05-08 2020-07-24 公安部物证鉴定中心 唾液斑迹dna和rna同时提取的方法
MX2023002980A (es) 2020-09-14 2023-06-06 Janssen Pharmaceutica Nv Terapias de combinación de inhibidores del fgfr.
CN112143815B (zh) * 2020-11-25 2021-02-26 江苏申基生物科技有限公司 一种用于检测人fgfr2基因融合突变的核酸组合物、试剂盒及检测方法
EP4340840A1 (en) 2021-05-19 2024-03-27 JANSSEN Pharmaceutica NV Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
EP4415692A1 (en) 2021-10-12 2024-08-21 TARIS Biomedical LLC Erdafitinib formulations and systems for intravesical administration
CN119072311A (zh) 2022-02-18 2024-12-03 塔里斯生物医药公司 用于膀胱内施用的厄达替尼制剂和渗透系统
CN120731076A (zh) 2023-02-13 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌
JP2026505598A (ja) 2023-02-13 2026-02-16 ヤンセン ファーマシューティカ エヌ．ベー． 高リスク筋層非浸潤性膀胱癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
JP2026506041A (ja) 2023-02-17 2026-02-20 タリス バイオメディカル エルエルシー 膀胱がんの治療における使用のための膀胱内投与のためのエルダフィチニブ
WO2025059602A1 (en) 2023-09-14 2025-03-20 Taris Biomedical Llc Methods of treating bladder cancer using intravesical administration of erdafitinib
CN119219611B (zh) * 2024-12-03 2025-04-18 南京诺源医疗器械有限公司 用于主动靶向成纤维细胞生长因子受体的近红外荧光探针及其制备方法与应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
AU5214500A (en) 1999-05-05 2000-11-21 Centre National De La Recherche Scientifique (C.N.R.S.) Means for detecting and treating pathologies linked to fgfr3
ATE437962T1 (de) 2002-10-01 2009-08-15 Epigenomics Ag Verfahren für die behandlung von proliferativen erkrankungen von brustzellen
DE602004022266D1 (de) * 2003-03-26 2009-09-10 Progenika Biopharma Sa Lkarzinoms der blase
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP1659175A1 (en) * 2004-11-18 2006-05-24 Institut Curie Alterations in seborrheic keratoses and their applications
MX2007014782A (es) 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
WO2007061130A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
JP2009523410A (ja) 2005-12-08 2009-06-25 ノバルティス アクチエンゲゼルシャフト 遺伝子転写に対するｆｇｆｒ３の阻害剤の効果
EP1918376A1 (en) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
KR20090123870A (ko) 2007-02-27 2009-12-02 노파르티스 아게 섬유모세포 성장 인자 수용체 또는 이의 변이체에 의해 매개되는 신호전달의 조정에 대한 감수성을 나타내는 세포의 확인 방법
WO2008109369A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
CA2754884C (en) 2007-06-21 2013-04-30 Gen-Probe Incorporated Methods of concentrating an analyte
US8071338B2 (en) 2007-08-08 2011-12-06 Roche Molecular Systems, Inc. Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity
WO2013173480A1 (en) 2012-05-15 2013-11-21 Predictive Biosciences, Inc. Detection of bladder cancer recurrence
WO2013173485A1 (en) 2012-05-15 2013-11-21 Predictive Biosciences, Inc. Detection of bladder cancers
GB0718542D0 (en) 2007-09-22 2007-10-31 Univ Dundee Targeted modulation of gene expression
AR073770A1 (es) 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
WO2010111625A1 (en) 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
WO2011027219A1 (en) 2009-09-04 2011-03-10 Progenika Biopharma, S.A. High throughput detection of small genomic deletions and insertions
WO2011115937A1 (en) * 2010-03-14 2011-09-22 The Translational Genomics Research Institute Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) * 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102293770A (zh) * 2011-05-25 2011-12-28 温州医学院 新型成纤维细胞生长因子受体酪氨酸激酶抑制剂
CN102319224B (zh) * 2011-07-27 2013-03-20 赛乐医药科技(上海)有限公司 复方甲氧那明的速释－缓释渗透泵制剂
HK1199066A1 (en) 2011-08-18 2015-06-19 Nestec S.A. Compositions and methods for detecting allelic variants
WO2013089882A2 (en) * 2011-09-27 2013-06-20 The Regents Of The University Of Michigan Recurrent gene fusions in breast cancer
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
WO2013088191A1 (en) * 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
EA026953B1 (ru) * 2012-02-28 2017-06-30 Астеллас Фарма Инк. Азотсодержащее ароматическое гетероциклическое соединение
HK1205528A1 (en) 2012-03-08 2015-12-18 Astellas Pharma Inc. Novel fgfr3 fusion product
US9254288B2 (en) * 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
GB201209609D0 (en) * 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
JPWO2014007369A1 (ja) * 2012-07-05 2016-06-02 国立研究開発法人国立がん研究センター Ｆｇｆｒ２融合遺伝子
CN104797936B (zh) * 2012-07-24 2017-11-24 纽约市哥伦比亚大学理事会 融合蛋白及其方法
CA2878183A1 (en) * 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
CA2886002C (en) * 2012-09-27 2020-06-09 Chugai Seiyaku Kabushiki Kaisha Fgfr3 fusion gene and pharmaceutical drug targeting same
CA2890346A1 (en) * 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
EP2945652B1 (en) * 2013-01-18 2021-07-07 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014165710A2 (en) 2013-04-05 2014-10-09 Life Technologies Corporation Gene fusions
WO2014193229A2 (en) 2013-05-27 2014-12-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Novel translocations in lung cancer
WO2015006723A1 (en) 2013-07-12 2015-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in cancer
US20200208224A1 (en) 2014-09-26 2020-07-02 Janssen Pharmaceutica Nv Use Of FGFR Mutant Gene Panels In Identifying Cancer Patients That Will Be Responsive To Treatment With An FGFR Inhibitor
EP4063516A1 (en) 2014-09-26 2022-09-28 Janssen Pharmaceutica NV Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
AU2018216969B2 (en) 2017-02-06 2024-04-11 Janssen Pharmaceutica Nv Cancer treatment

Also Published As

Publication number Publication date
BR112017006088A2 (pt) 2017-12-19
DK3198033T3 (da) 2022-04-11
IL324511A (en) 2026-01-01
KR20220162823A (ko) 2022-12-08
CN107002141B (zh) 2021-11-02
SG11201702381QA (en) 2017-04-27
CR20170104A (es) 2017-05-31
SV2017005415A (es) 2017-07-03
UY36325A (es) 2016-04-01
KR102470456B1 (ko) 2022-11-23
TW201619609A (zh) 2016-06-01
HRP20220496T1 (hr) 2022-05-27
KR20170062495A (ko) 2017-06-07
AU2021277633B2 (en) 2024-11-28
ES2912567T3 (es) 2022-05-26
JP6766037B2 (ja) 2020-10-07
UA122564C2 (uk) 2020-12-10
LT3198033T (lt) 2022-05-10
PH12017500556A1 (en) 2017-08-30
PL3198033T3 (pl) 2022-08-29
KR20250119657A (ko) 2025-08-07
SI3198033T1 (sl) 2022-06-30
US20240309463A1 (en) 2024-09-19
CA2962075C (en) 2025-09-09
MX392774B (es) 2025-03-24
MX2017003954A (es) 2017-12-14
CY1125190T1 (el) 2024-12-13
US20190078166A1 (en) 2019-03-14
ECSP17025787A (es) 2018-07-31
PT3198033T (pt) 2022-05-25
EP3198033A2 (en) 2017-08-02
MA40761B1 (fr) 2022-04-29
JP2017529090A (ja) 2017-10-05
GT201700059A (es) 2019-08-21
JP7558216B2 (ja) 2024-09-30
KR102839867B1 (ko) 2025-07-28
MX2022006536A (es) 2022-07-11
IL251264B (en) 2022-04-01
HUE058219T2 (hu) 2022-07-28
CN107002141A (zh) 2017-08-01
JP2020124192A (ja) 2020-08-20
AU2025201448A1 (en) 2025-03-20
SMT202200177T1 (it) 2022-05-12
EP3198033B1 (en) 2022-02-16
EP4063516A1 (en) 2022-09-28
ZA201702899B (en) 2019-06-26
TWI706136B (zh) 2020-10-01
EA201790716A1 (ru) 2017-10-31
CN113957146A (zh) 2022-01-21
RS63178B1 (sr) 2022-06-30
MY194567A (en) 2022-12-02
US20160090633A1 (en) 2016-03-31
US12037644B2 (en) 2024-07-16
IL291633A (en) 2022-05-01
AR102345A1 (es) 2017-02-22
MA40761A (fr) 2017-08-01
AU2021277633A1 (en) 2021-12-23
JP2022109910A (ja) 2022-07-28
IL291633B1 (en) 2025-12-01
JP2024112991A (ja) 2024-08-21
JP7051920B2 (ja) 2022-04-11
IL251264A0 (en) 2017-05-29
WO2016048833A2 (en) 2016-03-31
CA2962075A1 (en) 2016-03-31
CO2017003528A2 (es) 2017-07-11
CN113957146B (zh) 2026-04-03
AU2015321626B2 (en) 2021-12-16
AU2015321626A1 (en) 2017-04-06
WO2016048833A3 (en) 2016-05-19
NZ730886A (en) 2024-08-30
EA037920B1 (ru) 2021-06-07
IL291633B2 (en) 2026-04-01
JO3681B1 (ar) 2020-08-27

Similar Documents

Publication Publication Date Title
NI201700035A (es) Uso de paneles de genes mutantes del fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor del fgfr
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
MX2019010958A (es) Metodos de tratamiento de tumores.
PH12019502710A1 (en) Fgfr2 inhibitors for the treatment of cholangiocarcinoma
CO7151491A2 (es) Método para la identificación del origen de un cancer de origen primario desconocido
CL2019002438A1 (es) Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5.
MX2024001734A (es) Metodo de modificacion de diferenciacion e inmunidad de macrofagos.
MX2025004103A (es) Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa
TW201614237A (en) Markers for identifying patients responsive to anti-PD-L1 antibody therapy
MX2022014741A (es) Metodos para detectar bordetella.
BR112016028838A2 (pt) anticorpos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de detecção de lgr5 humano em uma amostra biológica, de detecção de um câncer, de identificação de um paciente com câncer, de seleção de um paciente com câncer para tratamento com um imunoconjugado e de tratamento de um paciente com câncer
SV2017005459A (es) Uso de los inhibidores de pan fgfr y método para identificación de pacientes con cáncer elegibles para el tratamiento con un inhibidor de pan fgfr
MX2022003916A (es) Uso de deteccion de marcador simultaneo para evaluar el glioma difuso y la respuesta al tratamiento.
MX2021003320A (es) Tratamiento del colangiocarcinoma.
PL408727A1 (pl) Zestaw diagnostyczny i sposób jednoczesnego wykrywania mutacji w obrębie genu NF1 dla grupy pacjentów z podejrzeniem choroby Recklinghausena
WO2019140008A3 (en) Methods for using dna methylation as a biomarker for identification and treatment of metabolic syndrome
AR086571A1 (es) Metodo para la identificacion del origen de un cancer de origen primario desconocido
PE20142434A1 (es) Metodo para la identificacion del origen de un cancer de origen primario desconocido
BR112017020582A2 (pt) composições e métodos para a detecção de um contaminante biológico